Skip to main content
Fig. 1 | BMC Geriatrics

Fig. 1

From: Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer

Fig. 1

Kaplan–Meier survival curves. A The median OS was 15.0 months(95% CI, 7.0–23.0). B The median PFS was 4.0 months (95% CI, 1.8–6.2). C The median PFS for patients with or without previous exposure to regorafenib (6.3 months vs 2.8 months) (P = 0.445). D The median PFS for patients with final high daily doses group (regorafenib > 80 mg) and low group(regorafenib ≤ 80 mg) (10.0 months vs 3.5 months) (P = 0.106)

Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us